Photodynamic Therapy of Pancreatic Cancer with Porphyrin-lipoprotein Photosensitizers
General Material Designation
[Thesis]
First Statement of Responsibility
Lai, Michelle
Subsequent Statement of Responsibility
Zheng, Gang
.PUBLICATION, DISTRIBUTION, ETC
Name of Publisher, Distributor, etc.
University of Toronto (Canada)
Date of Publication, Distribution, etc.
2019
GENERAL NOTES
Text of Note
62 p.
DISSERTATION (THESIS) NOTE
Dissertation or thesis details and type of degree
M.Sc.
Body granting the degree
University of Toronto (Canada)
Text preceding or following the note
2019
SUMMARY OR ABSTRACT
Text of Note
Previously, the high-density lipoprotein (HDL) mimicking porphyrin-lipoprotein (PLP) nanoparticle was found to accumulate more in tumours compared to their non-cancerous counterparts in several clinically relevant animal models. PLP demonstrates stability in blood circulation and rapid dissociation upon tumour accumulation to generate fluorescence and photodynamic reactivity. Photodynamic therapy (PDT) has been tested in pancreatic cancer patients with clinically approved photosensitizers; however, none are tumour selective. In this work, using in vitro tests with pancreatic adenocarcinoma cell line (PANC-1) and subcutaneous PANC-1 xenograft and orthotopic PANC-1 mouse models in vivo, it was demonstrated that PLP uptake more in pancreatic tumours compared to non-cancerous tissue. In addition, PLP combined with PDT (PLP-PDT) was effective in tumour destruction in vitro and in chronic studies with the subcutaneous PANC-1 xenograft mice. With the orthotopic PANC-1 mouse model, PLP-PDT treatment induced significantly more damage at the tumour site compared to non- cancerous pancreatic tissue.